The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...
When we examine vicarious trauma in Latino and other communities of color, we cannot separate individual experience from the ...
Welcome to Onc Nurse On Call, the new podcast from Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, ...
Erin Pierce, MSN, APRN, AOCNP, is an experienced advanced oncology nurse practitioner specializing in genitourinary cancers. She currently serves as a key member of the clinical team at HonorHealth ...
Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025. From clinical updates ...
Destiny-Breast09 PROs demonstrated higher quality of life and fewer gastrointestinal symptoms in patients with HER2-positive advanced breast cancer. Patient-reported outcomes (PROs) from the phase 3 ...
Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...
The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a right breast simple cyst, and a left breast indeterminate, oval, hypoechoic 1 ...
The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications. The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj ...
The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer. The FDA has approved fam-trastuzumab deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback